Literature DB >> 15803019

Aggressive fibromatosis.

William M Mendenhall1, Robert A Zlotecki, Christopher G Morris, Steven N Hochwald, Mark T Scarborough.   

Abstract

The purpose of this article is to review the pertinent literature and to define the optimal treatment of patients with aggressive fibromatosis. Data indicate the likelihood of local recurrence after surgery is high, particularly if margins are positive. Moderate-dose radiotherapy alone for gross disease or after a microscopically incomplete resection yields local control rates of approximately 75% to 80%. Treatment with pharmacologic agents results in objective response rates of approximately 40% to 50%; duration of response is variable. Thus, the optimal management for aggressive fibromatosis depends on tumor location and extent. Surgery is indicated if the lesion appears to be completely resectable with acceptable function and cosmesis. Radiotherapy is indicated for patients with unresectable tumors; those with positive margins after resection should be considered for adjuvant radiotherapy depending on the location and extent of the tumor. Pharmacologic treatment should be considered for patients with progressive disease after unsuccessful local-regional therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15803019     DOI: 10.1097/01.coc.0000144817.78549.53

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  13 in total

Review 1.  The enigma of desmoid tumors.

Authors:  Scott Okuno
Journal:  Curr Treat Options Oncol       Date:  2006-11

Review 2.  Targeted therapies: the rare cancer paradigm.

Authors:  Marco A Pierotti; Tiziana Negri; Elena Tamborini; Federica Perrone; Sabrina Pricl; Silvana Pilotti
Journal:  Mol Oncol       Date:  2009-10-28       Impact factor: 6.603

3.  Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis.

Authors:  Shu Li; Zhengfu Fan; Zhiwei Fang; Jiayong Liu; Chujie Bai; Ruifeng Xue; Lu Zhang; Tian Gao
Journal:  Chin J Cancer Res       Date:  2017-10       Impact factor: 5.087

4.  Case report of an intra-abdominal desmoid tumour presenting with bowel perforation.

Authors:  Mushtaq Shah; Bushra Azam
Journal:  Mcgill J Med       Date:  2007-07

5.  Postoperative recurrence of desmoid tumors: clinical and pathological perspectives.

Authors:  Yi-fei Wang; Wei Guo; Kun-kun Sun; Rong-li Yang; Xiao-dong Tang; Tao Ji; Shun Tang
Journal:  World J Surg Oncol       Date:  2015-02-07       Impact factor: 2.754

6.  Local recurrence of sporadic mesenteric fibromatosis following radical surgery attacking the proximal jejunum.

Authors:  Selçuk Gülmez; Ebubekir Gündeş; Aziz Serkan Senger; Orhan Uzun; Ulaş Aday; Hüseyin Çiyiltepe; Durmuş Ali Çetin; Emre Bozdağ; Kamuran Cumhur Değer; Erdal Polat
Journal:  Prz Gastroenterol       Date:  2017-09-30

7.  Radical palliative surgery: new limits to pursue.

Authors:  Mindy Young-Spint; Yigit S Guner; Frederick J Meyers; Phillip Schneider; Vijay P Khatri
Journal:  Pediatr Surg Int       Date:  2009-10       Impact factor: 1.827

8.  The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network.

Authors:  Brigitta G Baumert; Martin O Spahr; Arthur Von Hochstetter; Sylvie Beauvois; Christine Landmann; Katrin Fridrich; Salvador Villà; Michael J Kirschner; Guy Storme; Peter Thum; Hans K Streuli; Norbert Lombriser; Robert Maurer; Gerhard Ries; Ernst-Arnold Bleher; Alfred Willi; Juerg Allemann; Ulrich Buehler; Hugo Blessing; Urs M Luetolf; J Bernard Davis; Burkhardt Seifert; Manfred Infanger
Journal:  Radiat Oncol       Date:  2007-03-07       Impact factor: 3.481

9.  Diagnosis and treatment of extraabdominal desmoid fibromatosis.

Authors:  Mohamed Ghanem; Antje Heinisch; Christoph-E Heyde; Georg Freiherr von Salis-Soglio
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2014-02-24

10.  EXTRA-ABDOMINAL DESMOID TUMOR: LOCAL RECURRENCE AND TREATMENT OPTIONS.

Authors:  Luiz Eduardo Moreira Teixeira; Eugênio Costa Arantes; Rafael Freitas Villela; Claudio Beling Gonçalves Soares; Roberto Bitarães De Carvalho Costa; Marco Antônio Percope De Andrade
Journal:  Acta Ortop Bras       Date:  2016 May-Jun       Impact factor: 0.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.